ProKidney Corp/$PROK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ProKidney Corp
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
Ticker
$PROK
Sector
Primary listing
Employees
204
Headquarters
Website
ProKidney Corp Metrics
BasicAdvanced
$408M
-
-$0.56
1.81
-
Price and volume
Market cap
$408M
Beta
1.81
52-week high
$7.13
52-week low
$0.55
Average daily volume
2.5M
Financial strength
Current ratio
11.48
Quick ratio
10.491
Long term debt to equity
1.035
Total debt to equity
1.302
Interest coverage (TTM)
-35,263.40%
Profitability
EBITDA (TTM)
-170.192
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-13,752.18%
Operating margin (TTM)
-33,456.74%
Effective tax rate (TTM)
-0.49%
Management effectiveness
Return on assets (TTM)
-25.30%
Return on equity (TTM)
-40.51%
Valuation
Price to revenue (TTM)
737.125
Price to book
-0.4
Price to tangible book (TTM)
-0.4
Price to free cash flow (TTM)
-2.65
Free cash flow yield (TTM)
-37.73%
Free cash flow per share (TTM)
-1.14
Growth
Earnings per share change (TTM)
-7.29%
3-year earnings per share growth (CAGR)
28.45%
Bulls say / Bears say
Positive topline Phase 2 results for REGEN-007 demonstrated a 78% reduction in the annual decline of eGFR among patients receiving two rilparencel injections, showing significant stabilization in kidney function (Investing.com; RTTNews).
FDA alignment was secured on an accelerated approval pathway for Phase 3 PROACT 1 by confirming eGFR slope as a surrogate endpoint, nearly half of required patients are already enrolled, and key approval data is expected in Q2 2027 (Investing.com; RTTNews).
The company maintains a strong liquidity position with a current ratio of 11x and cash runway extending into mid-2027, supporting ongoing Phase 3 trials and reducing near-term financing concerns (Investing.com).
Evercore ISI pointed out that ongoing questions about the Phase 2 data, along with a Phase 3 readout not due until late 2026, could delay commercialization and increase investor uncertainty (MarketWatch).
PROK's stock surged 515% in one session with 45 volatility-related trading halts, showing speculative extremes that could quickly reverse if clinical or regulatory expectations aren't met (MarketWatch).
ProKidney recorded a net loss of $163.3 million in 2024, including $127.7 million in R&D expenses, highlighting high cash burn without current revenue—raising the risk of future dilution to support operations (GuruFocus).
Data summarised monthly by Lightyear AI. Last updated on 14 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ProKidney Corp stock?
ProKidney Corp (PROK) has a market cap of $408M as of October 12, 2025.
What is the P/E ratio for ProKidney Corp stock?
The price to earnings (P/E) ratio for ProKidney Corp (PROK) stock is 0 as of October 12, 2025.
Does ProKidney Corp stock pay dividends?
No, ProKidney Corp (PROK) stock does not pay dividends to its shareholders as of October 12, 2025.
When is the next ProKidney Corp dividend payment date?
ProKidney Corp (PROK) stock does not pay dividends to its shareholders.
What is the beta indicator for ProKidney Corp?
ProKidney Corp (PROK) has a beta rating of 1.81. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.